Cargando…
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to partici...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855735/ https://www.ncbi.nlm.nih.gov/pubmed/36672673 http://dx.doi.org/10.3390/biomedicines11010165 |
_version_ | 1784873448407826432 |
---|---|
author | Persano, Irene Cani, Massimiliano Del Rio, Benedetta Ferrari, Giorgia Garbo, Edoardo Parlagreco, Elena Pisano, Chiara Cetoretta, Valeria Delcuratolo, Marco Donatello Turco, Fabio Audisio, Alessandro Cecchi, Cristina Leone, Gianmarco Napoli, Valerio Maria Bertaglia, Valentina Bianco, Valentina Capelletto, Enrica D’Amiano, Carmen Di Maio, Massimo Gianetta, Martina Novello, Silvia Passiglia, Francesco Scagliotti, Giorgio Vittorio Bironzo, Paolo |
author_facet | Persano, Irene Cani, Massimiliano Del Rio, Benedetta Ferrari, Giorgia Garbo, Edoardo Parlagreco, Elena Pisano, Chiara Cetoretta, Valeria Delcuratolo, Marco Donatello Turco, Fabio Audisio, Alessandro Cecchi, Cristina Leone, Gianmarco Napoli, Valerio Maria Bertaglia, Valentina Bianco, Valentina Capelletto, Enrica D’Amiano, Carmen Di Maio, Massimo Gianetta, Martina Novello, Silvia Passiglia, Francesco Scagliotti, Giorgio Vittorio Bironzo, Paolo |
author_sort | Persano, Irene |
collection | PubMed |
description | Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to participate in our vaccination campaign received BNT162b2 and were included in the descriptive analysis. An anonymous questionnaire investigating the occurrence of SEs/AEs and PROs was administered to the study population 21 days after the first dose. Pearson’s chi-squared test was used to estimate the risk of experiencing SEs/AEs according to selected variables. A total of 997 patients were included in the study: 62.0% had stage IV cancer, and 68.8% were receiving an active treatment, of whom 15.9% were receiving immunotherapy. SEs/AEs were recorded in 37.1% of cases after the first dose and in 48.5% of cases after the second dose. The most common SEs were muscle pain/local rash (27.9% and 28%, after the first and second dose, respectively). Patients older than 70 years showed lower risk of SEs/AEs, while women showed a higher risk. Before receiving the vaccine, 18.2% of patients felt fearful and/or insecure about the vaccination. After the first dose, 57.5% of patients changed their feelings positively. Our data support the short-term safety of BNT162b2 in CPs, regardless of disease stage and concurrent treatments. Overall, the vaccination showed a positive impact on quality of life. |
format | Online Article Text |
id | pubmed-9855735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98557352023-01-21 Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience Persano, Irene Cani, Massimiliano Del Rio, Benedetta Ferrari, Giorgia Garbo, Edoardo Parlagreco, Elena Pisano, Chiara Cetoretta, Valeria Delcuratolo, Marco Donatello Turco, Fabio Audisio, Alessandro Cecchi, Cristina Leone, Gianmarco Napoli, Valerio Maria Bertaglia, Valentina Bianco, Valentina Capelletto, Enrica D’Amiano, Carmen Di Maio, Massimo Gianetta, Martina Novello, Silvia Passiglia, Francesco Scagliotti, Giorgio Vittorio Bironzo, Paolo Biomedicines Article Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to participate in our vaccination campaign received BNT162b2 and were included in the descriptive analysis. An anonymous questionnaire investigating the occurrence of SEs/AEs and PROs was administered to the study population 21 days after the first dose. Pearson’s chi-squared test was used to estimate the risk of experiencing SEs/AEs according to selected variables. A total of 997 patients were included in the study: 62.0% had stage IV cancer, and 68.8% were receiving an active treatment, of whom 15.9% were receiving immunotherapy. SEs/AEs were recorded in 37.1% of cases after the first dose and in 48.5% of cases after the second dose. The most common SEs were muscle pain/local rash (27.9% and 28%, after the first and second dose, respectively). Patients older than 70 years showed lower risk of SEs/AEs, while women showed a higher risk. Before receiving the vaccine, 18.2% of patients felt fearful and/or insecure about the vaccination. After the first dose, 57.5% of patients changed their feelings positively. Our data support the short-term safety of BNT162b2 in CPs, regardless of disease stage and concurrent treatments. Overall, the vaccination showed a positive impact on quality of life. MDPI 2023-01-09 /pmc/articles/PMC9855735/ /pubmed/36672673 http://dx.doi.org/10.3390/biomedicines11010165 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Persano, Irene Cani, Massimiliano Del Rio, Benedetta Ferrari, Giorgia Garbo, Edoardo Parlagreco, Elena Pisano, Chiara Cetoretta, Valeria Delcuratolo, Marco Donatello Turco, Fabio Audisio, Alessandro Cecchi, Cristina Leone, Gianmarco Napoli, Valerio Maria Bertaglia, Valentina Bianco, Valentina Capelletto, Enrica D’Amiano, Carmen Di Maio, Massimo Gianetta, Martina Novello, Silvia Passiglia, Francesco Scagliotti, Giorgio Vittorio Bironzo, Paolo Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
title | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
title_full | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
title_fullStr | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
title_full_unstemmed | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
title_short | Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience |
title_sort | short-term safety and psychosocial impact of the bnt162b2 mrna covid-19 vaccine in cancer patients—an italian single-center experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855735/ https://www.ncbi.nlm.nih.gov/pubmed/36672673 http://dx.doi.org/10.3390/biomedicines11010165 |
work_keys_str_mv | AT persanoirene shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT canimassimiliano shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT delriobenedetta shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT ferrarigiorgia shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT garboedoardo shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT parlagrecoelena shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT pisanochiara shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT cetorettavaleria shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT delcuratolomarcodonatello shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT turcofabio shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT audisioalessandro shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT cecchicristina shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT leonegianmarco shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT napolivaleriomaria shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT bertagliavalentina shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT biancovalentina shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT capellettoenrica shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT damianocarmen shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT dimaiomassimo shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT gianettamartina shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT novellosilvia shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT passigliafrancesco shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT scagliottigiorgiovittorio shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience AT bironzopaolo shorttermsafetyandpsychosocialimpactofthebnt162b2mrnacovid19vaccineincancerpatientsanitaliansinglecenterexperience |